ABBV 10-Q Quarterly Report June 30, 2018 | Alphaminr

ABBV 10-Q Quarter ended June 30, 2018

ABBVIE INC.
10-Ks and 10-Qs
10-Q
Quarter ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-Q
Quarter ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-Q
Quarter ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-Q
Quarter ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-K
Fiscal year ended Dec. 31, 2014
10-Q
Quarter ended Sept. 30, 2014
10-Q
Quarter ended June 30, 2014
10-Q
Quarter ended March 31, 2014
10-K
Fiscal year ended Dec. 31, 2013
10-Q
Quarter ended Sept. 30, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-K
Fiscal year ended Dec. 31, 2012
PROXIES
DEF 14A
Filed on March 18, 2024
DEF 14A
Filed on March 20, 2023
DEF 14A
Filed on March 21, 2022
DEF 14A
Filed on March 22, 2021
DEF 14A
Filed on March 23, 2020
DEF 14A
Filed on March 22, 2019
DEF 14A
Filed on March 19, 2018
DEF 14A
Filed on March 20, 2017
DEF 14A
Filed on March 21, 2016
DEF 14A
Filed on March 20, 2015
DEF 14A
Filed on March 24, 2014
DEF 14A
Filed on March 15, 2013
TABLE OF CONTENTS
Part IItem 1. Financial Statements and Supplementary DataNote 1 Basis Of PresentationNote 2 Revenue RecognitionNote 3 Supplemental Financial InformationNote 4 Earnings Per ShareNote 5 Licensing, Acquisitions and Other ArrangementsNote 6 Collaboration with Janssen Biotech, IncNote 7 Goodwill and Intangible AssetsNote 8 Restructuring PlansNote 9 Financial Instruments and Fair Value MeasuresNote 10 Post-employment BenefitsNote 11 EquityNote 12 Income TaxesNote 13 Legal Proceedings and ContingenciesNote 14 Segment InformationItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II. Other InformationPart IIItem 1. Legal ProceedingsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 6. Exhibits

Exhibits

10.1 *364-Day Term Loan Credit Agreement, dated as of May17, 2018, among AbbVie, the lenders and other parties party thereto, and Bank of America, N.A., as administrative agent (incorporated by reference to Exhibit10.1 of the companys Current Report on Form8-K filed on May18, 2018). 12.1 Ratio of Earnings to Fixed Charges 12.2 Computation of Ratio of Earnings to Fixed Charges 31.1 Certification of Chief Executive Officer Required by Rule13a-14(a)(17 CFR 240.13a-14(a)). 31.2 Certification of Chief Financial Officer Required by Rule13a-14(a)(17 CFR 240.13a-14(a)). 32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section1350, as adopted pursuant to Section906 of the Sarbanes-Oxley Act of 2002. 32.2 Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section1350, as adopted pursuant to Section906 of the Sarbanes-Oxley Act of 2002.